Skip to main content

German regulator OKs Emergent Bio’s large-scale BioThrax manufacturing facility, well-positioned for eventual approval in EU – Emergent BioSolutions Inc. (NYSE:EBS) | Seeking Alpha

By January 30, 2017News
emergent-biosolution-logo

emergent-biosolution-logo

The Germany Federal Ministry of Health’s Paul-Ehrlich-Institut (PEI) has approved Emergent BioSolutions’ (EBS -1.4%) large-scale Lansing, MI-based manufacturing site, Building 55, that will make its anthrax vaccine BioThrax. The approval allows product made there to be marketed in Germany, the only anthrax vaccine so licensed.

{iframe}http://seekingalpha.com/news/3238386-german-regulator-oks-emergent-bios-large-scale-biothrax-manufacturing-facility-well?utoken=77cea408193abfd0b8876d8484dacaab#email_link{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.